Surprisingly cMO and iMO from DLBCL showed common deregulated pathways with an enrichment for FCGR3A, CD36, FCGR1A, CYBB, AIM2, STAT6, FCGR2A, CCR2, NLRC4, S100A8, and CD14. These genes are broadly expressed in cMO in healthy samples (2, 5) and our results suggest that iMO and cMO are tumor-educated and polarized to a common inflammatory phenotype in DLBCL. The gene discussed is STAT6; the disease is neoplasm.